Lenalidomid Alkaloid-Int (Lenalidomide)

Lenalidomide exerts its therapeutic effect by binding to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the ubiquitination and degradation of transcription factors Ikaros and Aiolos. The resulting actions include modulation of the immune response, inhibition of new blood‑vessel formation, and direct anti‑proliferative activity against malignant plasma cells.

The specific dose of Lenalidomid Alkaloid-Int is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and overall health status. Dosage regimens can vary widely between indications and individual treatment plans, so the prescriber sets the appropriate amount and schedule for each patient.

Lenalidomid Alkaloid-Int is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception throughout treatment and for a defined period after the last dose. Safety during breastfeeding has not been established, and the drug is generally not recommended for nursing mothers.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The team then confirms pricing, availability, shipping details (including any cold‑chain requirements), and assists with necessary import documentation.

Lenalidomid Alkaloid-Int belongs to the class of immunomodulatory imide drugs (IMiDs), which differ from proteasome inhibitors and monoclonal antibodies commonly used in multiple myeloma. While IMiDs primarily modulate the immune environment and degrade specific transcription factors, proteasome inhibitors block protein degradation pathways, and antibodies target surface antigens. Choice of therapy depends on disease characteristics, prior treatment exposure, and patient tolerance.

Lenalidomid Alkaloid-Int should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging to protect it from moisture and light. Do not store in areas with high humidity or extreme heat, and keep it out of reach of children.

The medication is supplied as an oral tablet that patients swallow with water. It is typically taken once daily on a schedule prescribed by the treating physician, often in cycles that include treatment days followed by rest periods. Patients should follow the exact dosing instructions provided by their healthcare professional.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia leading to heightened infection susceptibility, and the potential for secondary malignancies. Patients should be monitored regularly for signs of blood clots, infections, and any new cancer development, and appropriate preventive measures should be taken.

Lenalidomid Alkaloid-Int is contraindicated in pregnant women and should not be used by individuals who cannot practice effective contraception. Patients with uncontrolled severe infections, significant hypersensitivity to lenalidomide or any formulation excipients, and those with certain uncontrolled cardiac or vascular conditions may also be advised against its use. A thorough medical assessment by a qualified clinician is essential before initiating therapy.